Urinary LRRK2 phosphorylation predicts parkinsonian phenotypes in G2019S <i>LRRK2</i> carriers
Kyle Fraser(Brigham and Women's Hospital), Birgitt Schüele, Jean‐Christophe Corvol(Centre National de la Recherche Scientifique), Susan Bressman(Icahn School of Medicine at Mount Sinai), J.F. Martí-Massó, Alexis Brice(Inserm), Roy N. Alcalay(Columbia University), Nir Giladi(Tel Aviv University), Jan Aasly(Norwegian University of Science and Technology), Emily M. Drabant, Tatiana Foroud(University of Southern California), Matthew J. Farrer(University of Florida), Mark S. Moehle(University of Florida), Thomas Gasser(Hertie Institute for Clinical Brain Research), Andrew B. West(Duke Medical Center), Eduardo Tolosa(Biomedical Research Networking Center on Neurodegenerative Diseases), Connie Maras, Karen Marder(Columbia University Irving Medical Center), Fayçal Hentati(National Institute of Neurology Mongi-Ben Hamida), Anthony E. Lang(University of Toronto), Piu Chan(Capital Medical University), Daniela Berg(Christian-Albrechts-Universität zu Kiel)
Cited by 138
Related Papers
MDS clinical diagnostic criteria for Parkinson's disease
|Movement Disorders|2015|7.4k
Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria
|Movement Disorders|2017|2.3k
Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease
|New England Journal of Medicine|2009|2.1k
Genome-wide association study reveals genetic risk underlying Parkinson's disease
|Nature Genetics|2009|2k
MDS research criteria for prodromal Parkinson's disease
|Movement Disorders|2015|1.3k